Nor in Medical Technology
Navigation Links
Nor in Medical Technology
...ly and requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Insulin, however, is not a cure for diabetes, nor does it prevent its eventual and devastating complications which may include kidney failure, blindness, heart disease, stroke, and amputation.
...
...ed or implied by such statements. There can be no guarantee that Tekturna or Tekturna HCT will be approved for any additional indications or labeling. nor can there be any guarantee that Tekturna or Tekturna HCT will achieve any particular levels of revenue in the future. In particular, management's expe...
...ubsequent filings, are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) About...
...rademarks of Mead Johnson & Co. Similac(R) Advance(R) are registered trademarks of Abbott Laboratories. PBM store-brand formula is neither made by nor affiliated with Mead Johnson or Abbott Laboratories. Contact: Joe Shields Director of Public Relations (800)...
...subsequent filings, are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) Abou...
...subsequent filings, are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) Abou...
...antee that Afinitor will be approved for sale in any additional markets, or that Afinitor will be approved for any additional indications or labeling. nor can there be any guarantee that Afinitor will achieve any particular levels of revenue in the future. In particular, management's expectations regardi...
...d their prescription after the grace period of twice the duration of their prescription had elapsed. This database analysis was neither designed nor intended to compare the safety and efficacy of the 5-ASA products and no such conclusions can be drawn from its results. About LIALDA Import...
...hich is available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law. Registered in England & Wales: No. 3888792 ...
...ements expressed or implied by such statements. There can be no guarantee that any such development compounds will be approved for sale in any market. nor can there be any guarantee that any of the existing products referred to in this release will be approved for any additional indications or labeling i...
... Cautionary statement regarding forward-looking statements. Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future event...
... injections multiple times or use a pump - each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its eventual and devastating complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. Since...
...www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Johnson & Johnson Pharmaceutical Research & Development, L.L.C. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.] M...
...ey Dean at LDean@AUAnet.org " target="_new"> LDean@AUAnet.org . Kaplan, S; Chung, D; Sandhu, J; Te, A. Generic substitutes are neither as safe nor effective as branded medications: experience in men treated for lower urinary tract symptoms (LUTS). J Urol, suppl. 2009: 181, 4, abstract 1799 ...
...er, there were more serious infections in the treatment group (25 vs. 3), although these were not linked to neutropenia. None were unexpected events, nor was there a pattern to them. In the primary analysis, PEGINTRON maintenance therapy was not superior to observational control in preventing the...
...in any additional markets. Neither can there be any guarantee that Afinitor will be approved for any additional indications or labeling in any market. nor can there be any guarantee that Afinitor will achieve any particular levels of revenue in the future. In particular, management's expectations regardi...
...3 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia. In Study HBBI, neither LY2140023 monohydrate, nor the comparator molecule olanzapine, known to be more effective than placebo, separated from placebo. In this particular study, Lilly observed a greate...
...ill provide information satisfactory to the FDA or that the FDA will allow Phase II clinical trials of Oxycyte in TBI to proceed in the United States. nor can there be any assurance that the planned dose escalation studies in Switzerland or any other country will not be delayed by regulators there or tha...
...ressed or implied by such statements. There can be no guarantee that Zometa will be approved for any additional indications or labeling in any market. nor can there be any guarantee that Zometa will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...CV PI tested in human liver microsomes and primary hepatocytes similar to ritonavir. In addition, SPI-452 demonstrated no inherent antiviral activity, nor did it affect the antiviral potency of these HIV PIs in in vitro cell assay. The ability of SPI-452 to enhance the pharmacokinetic exposure of ...
...ct against HIV, the trial indicated that PRO2000 was at least 30% more effective than any other arm in the study in preventing HIV. Neither BufferGel nor PRO2000 showed protection against any other sexually transmitted infection. After disappointing results from several previous microbicide trial...
...ts expressed or implied by such statements. There can be no guarantee that RAD001 will be approved for sale for any oncology indication in any market. nor can there be any guarantee that RAD001 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...uch statements. There can be no guarantee that Sandostatin LAR will be submitted or approved for any additional indications or labeling in any market. nor can there be any guarantee that RAD001 will be approved for sale for any oncology indication in any market. Neither can there be any guarantee that Sa...
...ts expressed or implied by such statements. There can be no guarantee that RAD001 will be approved for sale for any oncology indication in any market. nor can there be any guarantee that RAD001 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...lied by such statements. There can be no guarantee that Femara will be submitted or approved for any additional indications or labeling in any market. nor can there be any guarantee that Femara will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...essed or implied by such statements. There can be no guarantee that Tasigna will be approved for any additional indications or labeling in any market. nor can there be any guarantee regarding the long-term impact of a patient's use of Tasigna. Neither can there be any guarantee that Tasigna will achieve ...
...which is available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law. NOTES: (*) The percentage of patients whose tumor sh...
...professional strongly recommended immunization for their family. Forty percent of respondents also said health-care professionals neither recommended, nor discussed, influenza immunization for themselves. CDC this year expanded its recommendations for annual influenza vaccination to include all ...
...essed or implied by such statements. There can be no guarantee that Xolair will be approved for any additional indications or labelling in any market. nor can there be any guarantee that Xolair will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...mulary leaves important clinical scenarios uncovered. We found that nearly one third of surveyed Medicare prescription drug plans carry neither Sutent nor Nexavar and one quarter fails to cover Avastin." Targeted Cancer Therapies: The Shift from Metastatic to Early-Stage Disease. Clinician and Payer At...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
...rm 10-K, as well as subsequent filings, are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Janssen nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) Co......ed or implied by such statements. There can be no guarantee that Tekturna or Tekturna HCT will be approved for any additional indications or labeling. nor can there be any guarantee that Tekturna or Tekturna HCT will achieve any particular levels of revenue in the future. In particular, management's expe...
PTSD Associated With Higher Alzheimer's/Dementia Risk; Moderate Alcohol Consumption May Lower it
...t Alzheimer's disease risk factors are often in the news, adults do not know about the relationship between Alzheimer's disease risk and heart health, nor that physical activity can be protective against dementia, according to new research reported today at the Alzheimer's Association 2009 International ......ubsequent filings, are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) About...
...rademarks of Mead Johnson & Co. Similac(R) Advance(R) are registered trademarks of Abbott Laboratories. PBM store-brand formula is neither made by nor affiliated with Mead Johnson or Abbott Laboratories. Contact: Joe Shields Director of Public Relations (800)...
...subsequent filings, are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) Abou...
...subsequent filings, are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.) Abou...
...antee that Afinitor will be approved for sale in any additional markets, or that Afinitor will be approved for any additional indications or labeling. nor can there be any guarantee that Afinitor will achieve any particular levels of revenue in the future. In particular, management's expectations regardi...
...d their prescription after the grace period of twice the duration of their prescription had elapsed. This database analysis was neither designed nor intended to compare the safety and efficacy of the 5-ASA products and no such conclusions can be drawn from its results. About LIALDA Import...
...hich is available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law. Registered in England & Wales: No. 3888792 ...
...ements expressed or implied by such statements. There can be no guarantee that any such development compounds will be approved for sale in any market. nor can there be any guarantee that any of the existing products referred to in this release will be approved for any additional indications or labeling i...
... Cautionary statement regarding forward-looking statements. Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future event...
... injections multiple times or use a pump - each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its eventual and devastating complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. Since...
Food and Drug Administration Accepts Isolagen's Biologics License Application for Full Review
...encies may be identified during full review of the BLA. Also, the acknowledgment of filing by the FDA does not mean that the FDA has issued a license, nor did the FDA represent any evaluation of the adequacy of the data submitted. About Isolagen, Inc. Isolagen(TM), Inc. (NYSE Amex: ILE ) i......www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Johnson & Johnson Pharmaceutical Research & Development, L.L.C. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.] M...
...ey Dean at LDean@AUAnet.org " target="_new"> LDean@AUAnet.org . Kaplan, S; Chung, D; Sandhu, J; Te, A. Generic substitutes are neither as safe nor effective as branded medications: experience in men treated for lower urinary tract symptoms (LUTS). J Urol, suppl. 2009: 181, 4, abstract 1799 ...
...er, there were more serious infections in the treatment group (25 vs. 3), although these were not linked to neutropenia. None were unexpected events, nor was there a pattern to them. In the primary analysis, PEGINTRON maintenance therapy was not superior to observational control in preventing the...
...in any additional markets. Neither can there be any guarantee that Afinitor will be approved for any additional indications or labeling in any market. nor can there be any guarantee that Afinitor will achieve any particular levels of revenue in the future. In particular, management's expectations regardi...
...3 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia. In Study HBBI, neither LY2140023 monohydrate, nor the comparator molecule olanzapine, known to be more effective than placebo, separated from placebo. In this particular study, Lilly observed a greate...
...ill provide information satisfactory to the FDA or that the FDA will allow Phase II clinical trials of Oxycyte in TBI to proceed in the United States. nor can there be any assurance that the planned dose escalation studies in Switzerland or any other country will not be delayed by regulators there or tha...
Treating Knee Ligament Injuries
...Disclosure : The authors did not receive any outside funding or grants in support of their research for or preparation of this work. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entit......ressed or implied by such statements. There can be no guarantee that Zometa will be approved for any additional indications or labeling in any market. nor can there be any guarantee that Zometa will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...CV PI tested in human liver microsomes and primary hepatocytes similar to ritonavir. In addition, SPI-452 demonstrated no inherent antiviral activity, nor did it affect the antiviral potency of these HIV PIs in in vitro cell assay. The ability of SPI-452 to enhance the pharmacokinetic exposure of ...
...ct against HIV, the trial indicated that PRO2000 was at least 30% more effective than any other arm in the study in preventing HIV. Neither BufferGel nor PRO2000 showed protection against any other sexually transmitted infection. After disappointing results from several previous microbicide trial...
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
...signed study product vaginally up to one hour before each act of sexual intercourse. The gel arms were double-blinded so that neither the participant nor the study staff knew the identity of the assigned study product. Women in all four arms received a standard-of-care HIV prevention package, which incl......ts expressed or implied by such statements. There can be no guarantee that RAD001 will be approved for sale for any oncology indication in any market. nor can there be any guarantee that RAD001 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...uch statements. There can be no guarantee that Sandostatin LAR will be submitted or approved for any additional indications or labeling in any market. nor can there be any guarantee that RAD001 will be approved for sale for any oncology indication in any market. Neither can there be any guarantee that Sa...
ProUroCare Medical Inc. Announces Pricing of Equity Offering
...n. This press release does not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock or any other securities, nor will there be any sale of the shares of common stock or any other securities in any state of jurisdiction in which such offer, solicitation or sale wo...Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
...unds. The content of this publication does not necessarily reflect the views or policies of the United States Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Forward-Looking Statement This pre......ts expressed or implied by such statements. There can be no guarantee that RAD001 will be approved for sale for any oncology indication in any market. nor can there be any guarantee that RAD001 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...lied by such statements. There can be no guarantee that Femara will be submitted or approved for any additional indications or labeling in any market. nor can there be any guarantee that Femara will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...essed or implied by such statements. There can be no guarantee that Tasigna will be approved for any additional indications or labeling in any market. nor can there be any guarantee regarding the long-term impact of a patient's use of Tasigna. Neither can there be any guarantee that Tasigna will achieve ...
...which is available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law. NOTES: (*) The percentage of patients whose tumor sh...
Micromet Expands Committed Equity Financing Facility to $75 Million
...he warrants before January 30, 2009. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state which such offer, solicitation or sale would be unlawful prior to the registration or qualifi...Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
... activity and dietary strategies to prevent type II diabetes and cardiovascular disease is neither commercially viable for pharmaceutical corporations nor sufficiently funded by NIH and is thus "not likely to happen." A second M.D., wary of statins, objected to placing people on medications who ...Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
...lied the topical cream three times daily for 28 days. The study did not achieve statistical significance in its primary efficacy endpoint, nor in several secondary endpoints. The effect witnessed did not measure up to other topical NSAID (non-steroidal anti-inflammatory drug) products already......professional strongly recommended immunization for their family. Forty percent of respondents also said health-care professionals neither recommended, nor discussed, influenza immunization for themselves. CDC this year expanded its recommendations for annual influenza vaccination to include all ...
...essed or implied by such statements. There can be no guarantee that Xolair will be approved for any additional indications or labelling in any market. nor can there be any guarantee that Xolair will achieve any particular levels of revenue in the future. In particular, management's expectations regarding...
...mulary leaves important clinical scenarios uncovered. We found that nearly one third of surveyed Medicare prescription drug plans carry neither Sutent nor Nexavar and one quarter fails to cover Avastin." Targeted Cancer Therapies: The Shift from Metastatic to Early-Stage Disease. Clinician and Payer At...
Other TagsMedicinalAlertAlertAthleticSurgeSurgeSurgeSurgeSurgeSurgeOther Contentsdissectiondissectiondissectiondissectionapathyapathyaphasiaaphthousaplasticappendicitisareola
TastyDermatologistsMedicinalPessimisticAlertActonelIslamabadMisledBombayScinetistsAthleticAverageWaltzSurge
(Date:11/26/2009)..., Heidelberg, 27 November 2009 What are the bare... required to produce a cell that can survive on it...cell, and understand how an entire organism functi...ons that scientists in a partnership between the E...delberg, Germany, and the Centre de Regulacio Genm...
(Date:11/25/2009)...hrelin, a hormone produced in the stomach, may be ...ent of Parkinson,s disease, Yale School of Medicin...ent issue of the Journal of Neuroscience . , Pa...opamine neurons in an area of the midbrain known a...opamine production. Reduced production of dopamin...
(Date:11/25/2009)... Dr. Sarit Larisch, Head of the Cell Death Researc...nt of Biology, has been awarded the prestigious Jo...arch exploring the cause of brain cell damage in P...ch year to scientists in support of innovation and... officially conferred earlier this month at an eve...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Hormone ghrelin can boost resistance to Parkinson's disease 2Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Carnitine supplements reverse glucose intolerance in animals 9553 1Carnitine supplements reverse glucose intolerance in animals 9553 2New insights into limb formation 9549 1New insights into limb formation 9549 2Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 54355 1Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 54355 2Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 54355 3(Date:11/27/2009)...rm Replikins Ltd. today issued its latest biochemi...hows that the lethality of the virus has dropped f...current outbreak in the spring of 2009 to resting ...he H1N1 infectivity count, however, remains increa...ember 27, 2009 -- Biotech firm Replikins Ltd., whi...
(Date:11/27/2009)...nce, Nov. 27 Team Garmin-Slipstrea...dicated to ethical sporting and developing the nex... that it will become Team Garmin-Transitions with ...or of the team. Transitions Optical is the world,s...g the most advanced photochromic technology in the...
(Date:11/27/2009)... medical, economic burdens, study predicts , ...ber of people with diabetes in the United States i... study predicts. , That would bring the total b...se, up from 23.7 million today. , , At the same ...ll triple, the study also warns, rising from an es...
(Date:11/27/2009)... manufacturers who use medical load cells at the h...ars by bringing in technology partner Flintec earl...-active medical manufacturers are calling in Flint... projects, ensuring that progress will not be cons...y outdated technology. , ...
(Date:11/26/2009)...f Americans living with diabetes will nearly doubl...llion in 2034. Over the same period, spending on d...on to $336 billion, even with no increase in the p...versity of Chicago report in the December issue of...betes covered by Medicare will rise from 8.2 milli...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3[0] Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased[0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor[0] Diabetes Cases Expected to Double in 25 Years[0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells[0] Diabetes cases to double and costs to triple by 2034
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |